WuXi Biologics (Cayman)
(OTC) WXIBF
WuXi Biologics (Cayman) Financials at a Glance
Market Cap
$19.03B
Revenue (TTM)
$37.17B
Net Income (TTM)
$6.83B
EPS (TTM)
$0.14
P/E Ratio
32.15
Dividend
$0.00
Beta (Volatility)
0.43 (Low)
Dividend
$0.00
Beta (Volatility)
0.43 (Low)
Price
$4.60
Volume
5,000
Open
$4.60
Price
$4.60
Volume
5,000
Open
$4.60
Previous Close
$4.60
Daily Range
$4.60 - $4.60
52-Week Range
$2.26 - $5.61
Dividend
$0.00
Beta (Volatility)
0.43 (Low)
Price
$4.60
Volume
5,000
Open
$4.60
Previous Close
$4.60
Daily Range
$4.60 - $4.60
52-Week Range
$2.26 - $5.61
WXIBF News
WXIBF: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout WuXi Biologics (Cayman)
Industry
Life Sciences Tools and Services
Sector
Health CareEmployees
12,575
CEO
Zhi Sheng Chen, PhD
Website
www.wuxibiologics.comHeadquarters
Wuxi, 214092, CN
WXIBF Financials
Key Financial Metrics (TTM)
Gross Margin
43%
Operating Margin
29%
Net Income Margin
21%
Return on Equity
10%
Return on Capital
11%
Return on Assets
7%
Earnings Yield
3.11%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$19.03B
Shares Outstanding
4.14B
Volume
5.00K
Short Interest
0.00%
Avg. Volume
12.35K
Financials (TTM)
Gross Profit
$7.65B
Operating Income
$4.97B
EBITDA
$6.43B
Operating Cash Flow
$5.22B
Capital Expenditure
$3.93B
Free Cash Flow
$1.29B
Cash & ST Invst.
$10.71B
Total Debt
$4.94B
WuXi Biologics (Cayman) Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$9.95B
+17.2%
Gross Profit
$4.25B
+19.4%
Gross Margin
42.73%
N/A
Market Cap
$19.03B
N/A
Market Cap/Employee
$1.51M
N/A
Employees
12,575
N/A
Net Income
$2.34B
+3.2%
EBITDA
$3.45B
+29.6%
Quarterly Fundamentals
Net Cash
$7.43B
+109.2%
Accounts Receivable
$7.03B
+30.3%
Inventory
$1.66B
-15.8%
Long Term Debt
$2.12B
-45.0%
Short Term Debt
$2.98B
+133.0%
Return on Assets
6.94%
N/A
Return on Invested Capital
11.32%
N/A
Free Cash Flow
$93.66M
-142.8%
Operating Cash Flow
$1.81B
-22.6%